Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease

Chugai Pharmaceutical eked out a revenue rise of 3.1% in January-June as Japan sales of cancer and bone/joint disease portfolios performed strongly to offset a blow from biennial drug price cuts implemented in April. In the first half of FY2016,...read more